IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
28 mars 2022 08h00 HE
|
IN8bio, Inc
All three patients with high-risk or relapsed acute-myeloid leukemia (AML) dosed to-date with INB-100 demonstrated durable remissions at 23.3, 21.0, and 9.3 months post-BMT, respectively. Immune...
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
17 mars 2022 16h15 HE
|
IN8bio, Inc
All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), have shown a well-tolerated safety profile and longer than anticipated progression free...
IN8bio to present at March Investor and Scientific Conferences
04 mars 2022 07h00 HE
|
IN8bio, Inc
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations: ...
IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit
10 févr. 2022 17h36 HE
|
IN8bio, Inc
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be...
IN8bio to Present at Upcoming January Investor Conferences
10 janv. 2022 07h00 HE
|
IN8bio, Inc
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
06 janv. 2022 07h00 HE
|
IN8bio, Inc
INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort Cohort 1 dosing is complete with three patients...
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
16 déc. 2021 07h00 HE
|
IN8bio, Inc
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to...
IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer
09 déc. 2021 16h30 HE
|
IN8bio, Inc
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
16 nov. 2021 07h00 HE
|
IN8bio, Inc
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies...
IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
11 nov. 2021 07h00 HE
|
IN8bio, Inc
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...